T1	Participants 634 690	patients with locally advanced resectable gastric cancer
T2	Participants 711 759	156 patients with stage III or IV gastric cancer
T3	Participants 1179 1197	chemotherapy group
T4	Participants 1234 1247	control group
T5	Participants 1586 1613	limited number of patients,
